ACE and cardiovascular disorder: Likewise, in the Telmisartan Randomised Assessment Study in ACE-intolerant Subjects with Cardiovascular Disease (TRANSCEND), no difference was seen in AF incidence between treatment with telmisartan or placebo in patients with high-risk for cardiovascular disease (62, 88).